

**Supplementary Table SI.** Configurations of supplements used during TPE. This includes priming of the lines before TPE procedures and the administration of 20% albumin at the end of the procedure. NE subgroup (81 patients, 107 sessions, 360 TPEs), non-NE subgroup (97 patients, 107 sessions, 380 TPEs), entire studied population (178 patients, 214 sessions; 740 TPEs). Data are presented as percentages; *p*-value – Fisher’s exact test

Configurations of supplements used during TPE (% vs. No. of TPE)	NE subgroup, n (%)	Non-NE subgroup, n (%)	<i>P</i> -value	All studied population, n (%)
FFP + 5% Albumin	58 (16)	98 (25.8)	0.001	156 (21.1)
FFP + 5% Albumin + Ringer’s solution	33 (9.2)	49 (12.9)	NS	82 (11.1)
FFP + 5% Albumin + 6% HES	47 (13.1)	68 (17.9)	0.043	115 (15.5)
FFP + 6% HES	73 (20.3)	66 (17.4)	NS	139 (18.7)
FFP + Ringer’s solution	3 (0.8)	2 (0.5)	NS	5 (0.7)
FFP + 6% HES + Ringer’s solution	58 (16.1)	27 (7.1)	< 0.001	85 (11.5)
FFP + 5% Albumin + 6% HES + Ringer’s solution	2 (0.6)	9 (2.4)	0.039	11 (1.5)
<b>TPE with FFP (% vs. no. of TPE)</b>	<b>274 (76.1)</b>	<b>335 (88.2)</b>	<b>&lt; 0.001</b>	<b>609 (82.3)</b>
5% Albumin + 6% HES + Ringer’s solution	19 (5.3)	4 (1.1)	0.001	23 (3.1)
5% Albumin + Ringer’s solution	38 (10.5)	14 (3.7)	< 0.001	52 (7)
5% Albumin + 6% HES	10 (2.7)	1 (0.3)	0.004	11 (1.5)
5% Albumin	14 (3.9)	25 (6.5)	NS	39 (5.3)
6% HES + Ringer’s solution	5 (1.4)	1 (0.3)	NS	6 (0.8)
<b>TPE without FFP (% vs. no. of TPE)</b>	<b>86 (23.9)</b>	<b>45 (11.8)</b>	<b>&lt; 0.001</b>	<b>131 (17.7)</b>
<b>Lines priming (% vs. no. of TPE)</b>				
5% Albumin	97 (27)	144 (37.9)	0.001	241 (32.6)
0.9% Sodium chloride solution	225 (62.5)	229 (60.3)	NS	454 (61.4)
Ringer’s solution	26 (7.2)	3 (0.8)	< 0.001	29 (3.9)
6% HES	12 (3.3)	4 (1)	0.029	16 (2.2)
20% Albumin given at the end of TPE	70 (19.4)	61 (16.1)	NS	131 (17.7)

**Supplementary Table SII.** Location and size of vascular access, filters, and machines used for TPE. NE subgroup (81 patients, 107 sessions, 360 TPEs), non-NE subgroup (97 patients, 107 sessions, 380 TPEs), entire studied population (178 patients, 214 sessions, 740 TPEs). Data are presented as percentages; *p*-value – one-sided Fisher’s exact test

<b>Location of vascular access (% vs No. of TPE sessions)</b>	<b>NE subgroup, n (%)</b>	<b>Non-NE subgroup, n (%)</b>	<b>P-value</b>	<b>All studied population, n (%)</b>
Right internal jugular vein	14 (13.1)	39 (36.4)	0.001	53 (24.8)
Femoral vein	93 (86.9)	65 (60.7)	0.003	158 (73.8)
Other	0	3 (2.9)	NS	3 (1.4)
<b>Size of central venous catheter [8-12,5 Fr] (% vs No. of TPE sessions)</b>				
12,5	25 (23.4)	28 (26.2)	NS	53 (24.8)
11	40 (37.4)	28 (26.2)	NS	68 (31.8)
9	27 (25.2)	35 (32.7)	NS	63 (29.4)
8	15 (14)	16 (14.9)	NS	30 (14)
<b>Filter (% vs No. of TPE sessions)</b>				
TPE1000	225 (62.5)	275 (72.4)	0.003	500 (67.6)
TPE 2000	5 (1.4)	22 (5.8)	0.001	27 (3.7)
Fresenius P1S (PSN1)	69 (19.2)	46 (12.1)	0.005	115 (15.5)
BT 900 Hemaplex	61 (16.9)	34 (8.9)	0.001	95 (12.8)
Fresenius P2S	0	3 (0.8)	NS	3 (0.4)
<b>Machine (% vs. no. of TPE sessions)</b>				
Hospal	202 (56.1)	229 (60.3)	NS	431 (58.2)
Prisma	113 (31.4)	73 (19.2)	< 0.001	186 (25.2)
Prisma Flex	45 (12.5)	78 (20.5)	0.002	123 (16.6)